Date: 2014-03-28
Type of information: IPO
Company: Oncodesign (France)
Investors:
Amount: € 12.8 million
Funding type: IPO
Planned used: This capital increase is intended to provide Oncodesign with additional means to finance its operations and its development. The funds will be used to continue the development of new kinase inhibitors in oncology until the end of phase I / IIa and to carry out and engage new partnerships outside oncology.
Others: * On March 28, 2014, Oncodesign announced the success of its initial public offering on Alternext Paris. The company was listed through the admission to trading of 4,390,640 existing shares making up the company’s equity and the sale of 1,749,394 new shares issued under a Global Offering, including full exercise of the extension option. The over?allotment option was also fully exercised, with 77,882 shares sold. Total demand was €23.5 million, including an €11.6 million Global Placement and an €11.9 million Open Price Public Offering. The IPO raised €12.8 million altogether, with 40% allocated to individual investors. The admission and issue price of Oncodesign shares was set at €7.34 per share, at the high end of the indicative price range. The company’s market capitalisation stood at around €44.5 million on the issue date.
* On March 10, 2014, Oncodesign, a biotechnology company serving the pharmaceutical industry for the discovery of new therapeutic molecules against cancer and other serious diseases with no known effective treatment, has announced the launch of its IPO on Alternext Paris. CM- CIC Capital Innovation, one of the company shareholder , is committed to place an order for a total of €1 million, or 10% of the gross proceeds of the Offering. BPIFrance is also committed to place an order for a total of € 300 000 , or 3% of the gross amount of the Offer ( excluding Extension Clause and on the basis of a price equal to the midpoint of the indicative price range offer is € 6.88).
Therapeutic area: Cancer - Oncology
